1-丁基-4-哌啶酮 | 23081-86-9

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-丁基-4-哌啶酮
• 中文别名: N-丁基-4-哌啶酮
• 英文名称: 1-n-butyl-4-piperidone
• 英文别名: 1-butylpiperidin-4-one
• CAS: 23081-86-9
• 化学式: C₉H₁₇NO
• mdl: MFCD00023404
• 分子量: 155.24
• InChiKey: OCNWYKFGWLGNHZ-UHFFFAOYSA-N

物化性质

• 沸点：
  50°/0.1mm
• 密度：
  0.943±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P321,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储条件：2-8℃，请保持干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Butylpiperidin-4-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Butylpiperidin-4-one
CAS number: 23081-86-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H17NO
Molecular weight: 155.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-丁基-4-哌啶酮 在 palladium on activated charcoal 氢氧化钾 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， 20.0 ℃ 、275.79 kPa 条件下， 生成 5-amino-3-(1-butylpiperidin-4-yl)pyrrolo[3,2-b]pyridine
  参考文献：
  名称：

  Novel Potent 5-HT_1F Receptor Agonists:  Structure−Activity Studies of a Series of Substituted N-[3-(1-Methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides

  摘要：

  Compound 1a (LY334370), a selective 5-HT1F receptor agonist (SSOFRA), inhibited dural inflammation in the neurogenic plasma protein extravasation model of migraine and demonstrated clinical efficacy for the acute treatment of migraine. Although 1 was greater than 100-fold selective over both the 5-HT1B and 5-HT1D receptors, it exhibited appreciable 5-HT1A receptor affinity. Described here is the synthesis and evaluation of a series of pyrrolo[2,3-c]pyridine and pyrrolo[3,2-b]pyridine (2a and 3a) as well as pyrrolo[3,2-d]pyrimidine (4a) analogues of 1, compounds prepared in an effort to identify SSOFRAs with improved selectivity over other 5-HT1 receptor subtypes. The pyrrolo [3,2-b] pyridine analogue 3a showed high 5-HT1F receptor affinity but offered no improvement in selectivity compared to 1. However, the C-5 acetamide derivative, 3b, was greater than 100-fold selective over the 5-HT1A, 5-HT1B, and 5-HT1D receptors. SAR studies of this series determined that alkylamides in particular exhibited high selectivity for the 5-HT1F receptor. Replacement at C-5 with other substituents decreased affinity or selectivity. These SAR studies identified SSOFRAs that demonstrated oral activity in the neurogenic plasma protein extravasation model, a model indicative of antimigraine activity.

  DOI：

  10.1021/jm030020m
• 作为产物：
  描述：

  4-piperidone monohydrochloride monohydrate 在 potassium carbonate 、 正丁胺 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 以62%的产率得到1-丁基-4-哌啶酮
  参考文献：
  名称：

  Indazole derivatives having monocyclic amine

  摘要：

  一种具有以下化学式（I）的吲哚酮化合物：其中：R.sub.1为氢、C.sub.1-C.sub.6烷基、C.sub.3-C.sub.6烯基或C.sub.3-C.sub.6环烷基；Q为羰基、硫代羰基或亚甲基；R.sub.2为化学式（II）或（IV）的基团；其中R.sub.1为C.sub.1-C.sub.6烷基、C.sub.3-C.sub.6烯基或苄基，其中苄基的苯基部分可选择性地被相同或不同的卤素或甲氧基单取代或双取代；m为0至2；n和o为1或2。该化合物具有5-HT.sub.4受体激动剂活性。

  公开号：

  US05945434A1

文献信息

• 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS
  申请人：Shih Charles C-Y

  公开号：US20120046247A1

  公开（公告）日：2012-02-23

  This invention relates to compounds of Formula (I), (II), or (III) as shown in the specification, which contain a 1,5-diphenylpenta-1,4-dien-3-one backbone. These compounds can be used to treat cancer, inflammatory disease, or autoimmune disease.

  这项发明涉及到规范中所示的具有Formula (I)、(II)或(III)的化合物，这些化合物含有1,5-二苯基戊-1,4-二烯-3-酮骨架。这些化合物可用于治疗癌症、炎症性疾病或自身免疫疾病。
• Use of serotonin 5-HT1F agonists for the prevention of migraine
  申请人：ELI LILLY AND COMPANY

  公开号：EP0832650A3

  公开（公告）日：1998-09-02

  This invention provides methods for the prevention of migraine which comprises administering to a mammal in need thereof a serotonin 5-HT1F agonist.

  这项发明提供了预防偏头痛的方法，包括向需要的哺乳动物施用一种5-HT1F受体激动剂。
• Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis
  申请人：ELI LILLY AND COMPANY

  公开号：EP0824917A3

  公开（公告）日：2000-08-30

  This invention provides methods for the treatment or amelioration of the symptoms of the common cold or allergic rhinitis which comprises administering to a mammal in need thereof a serotonin 5-HT1F agonist.

  这项发明提供了治疗或缓解普通感冒或过敏性鼻炎症状的方法，包括向需要的哺乳动物施用一种5-HT1F受体激动剂。
• Methods of treating or ameliorating the symptoms of common cold or
  申请人：Eli Lilly and Company

  公开号：US05962473A1

  公开（公告）日：1999-10-05

  This invention provides methods for the treatment or amelioration of the symptoms of the common cold or allergic rhinitis which comprises administering to a mammal in need thereof a serotonin 5-HT.sub.1F agonist.

  这项发明提供了治疗或改善普通感冒或过敏性鼻炎症状的方法，包括向需要的哺乳动物施用一种5-羟色胺5-HT.sub.1F激动剂。
• 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)-and
  申请人：Eli Lilly and Company

  公开号：US05708008A1

  公开（公告）日：1998-01-13

  This invention provides novel 5-HT.sub.1F agonists of Formula I ##STR1## where A--B, R, R.sup.1 and X are as defined in the specification, which are useful for the treatment of migraine and associated disorders.

  这项发明提供了新颖的Formula I的5-HT.sub.1F激动剂，其中A-B、R、R.sup.1和X如规范中所定义，对治疗偏头痛及相关疾病有用。